Caught my eye
-
340B, Alzheimer’s, Caught my eye, Drug Prices, Drug shortages, Medicare Advantage, State-based ReformCaught my eye — 1/26/24
Read more: Caught my eye — 1/26/24It has been fun to see the year really start to kick off this week with a bunch of policy releases. Shortages. Generic shortages are caused by a myriad of factors, but a big piece is the race to the bottom for prices. A fraction of a penny less and a contract shifts to another…
-
Caught my eye — 1/12/24
Read more: Caught my eye — 1/12/24Aye-n’t going to happen. Last week I covered how Florida had their importation plan approved by the Food and Drug Administration. It all seems so unlikely to happen or, if it does, it has a lot to go through before it happens. And already the Canadians are saying no thank you. International Math. The Commonwealth…
-
Caught my eye — 1/5/24
Read more: Caught my eye — 1/5/24Orange you glad? Florida got approval from the Food and Drug Administration to import drugs from Canada. Ho-hum. The “how” still has to be figured out and approved and that isn’t easy. Canada has about the population of California. It doesn’t want to supply the United States with drugs. It’s one of those ideas that…
-
Caught my eye, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Pharmacy Benefit ManagersCaught my eye — 12/15/23
Read more: Caught my eye — 12/15/23Driving home (the message.) Yesterday President Biden drove up to the National Institutes of Health and gave a speech about drug prices. My main issue with it is the traffic caused by shutting down the beltway and all the roads around my neighborhood. Okay and I think that a lot of the inflation penalties for…
-
Caught my eye — 12/8/23
Read more: Caught my eye — 12/8/23Marching right past. Senator Bernie Sanders held up the head of the NIH hearings because he wanted to make sure march-in rights were part of the policy conversations on drug pricing. I can’t decide if march-in rights are like your 1st grade teacher asking for part of your salary because she was part of your…
-
Caught my eye — 12/1/23
Read more: Caught my eye — 12/1/23Patient no more. A few weeks ago I wrote about how thanks to the HIV Hepatitis Policy Institute, the Diabetes Leadership Council and the Diabetes Patient Advocacy Coalition and their suit against the Department of Health and Human Services, accumulator programs were dealt a blow. They can only be used if it is for a branded…
-
Caught my eye — 11/10/23
Read more: Caught my eye — 11/10/23Guess which one costs more. This Wall Street Journal article has been making the rounds this week. It highlights how if there are two prices for a drug, plans tend to prefer the higher cost one with higher rebates. I hesitate to call it news because it seems so obvious to those of us who…
-
Caught my eye — 11/3/23
Read more: Caught my eye — 11/3/23InNOvation. Seagen said they aren’t looking at a drug that would treat early-stage bladder cancer because it would be subject to negotiation too soon after approval and wouldn’t have a financial return on the investment. Today the National Pharmaceutical Council published a great piece in Health Affairs that goes deeper into the subject of innovation…
-
Caught my eye — 10/27/23
Read more: Caught my eye — 10/27/23Caught my ear? This story on NPR about drug shortages and how one woman is trying to plug the holes was fantastic. Two takeaways – (1) never underestimate a mother whose kid needs help and (2) figuring out drug shortages should be more systematic and not a game of “whack a mole.” Nothing but net.…
-
Caught my eye — 10/13/23
Read more: Caught my eye — 10/13/23Medicare Math. Medicare Part B premiums will go up about 6% next year, Social Security cost of living adjustment will be 3.2%. Really Stupid Vaccine Policies. Sometimes a story hits just right like this Washington Post opinion piece on RSV vaccines for adults and how the access is harmed by coverage policies. This year two…
Latest news
- Caught my eye — 1/24/25
- Caught my eye — 1/16/25
- Caught my eye — 1/10/25
- Caught my eye — 12/20/24
- Nurturing the Potential of Biosimilars
Categories
- 340B (31)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (19)
- Caught my eye (53)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (28)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (4)
- Health Equity (3)
- Healthcare Costs (24)
- ICER (7)
- Importation (2)
- Inflation Reduction Act (42)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (13)
- Medicare Negotiation (44)
- Medicare Part D (40)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (25)
- Reference Pricing (4)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (8)